Resource Library

At the 2024 MDIC Annual Public Forum, the Commercial Payer Council hosted an insightful session on the transformative role of GLP-1 receptor agonists in obesity care and their ripple effect across the traditional MedTech landscape. These groundbreaking drugs are not only redefining diabetes management, but are also influencing fields such as cardiovascular health, orthopedics, and beyond.

Session Highlights

Moderated by Keely Scamperle and Chandra Branham, the session titled “The GLP-1 Revolution: Transforming Metabolic Health and Obesity Treatment” brought together senior medical officers, reimbursement strategists, and industry experts. The discussion focused on the opportunities and challenges posed by GLP-1 drugs for payers, medical device companies, and patients.

Key insights included:

• The importance of a comprehensive, multi-faceted approach to obesity management.
• Emerging market opportunities for surgical interventions in patients previously considered ineligible for certain procedures.
• How GLP-1 drugs are creating new avenues for managing chronic conditions like cardiovascular disease and diabetes, reshaping traditional reimbursement models.

Special thanks to Derek van Amerongen, MD, MS, Joel Brill, and Lee Fleisher for their invaluable contributions to the discussion.

Download the Session Summary

Want to dive deeper into the key takeaways from this session? Download the full session summary using the download button below to explore the transformative potential of GLP-1 drugs and how they are changing the landscape of medical care.

Stay Connected with MDIC’s HEPV Initiative

We invite you to learn more about MDIC’s Health Economics and Patient Value (HEPV) initiative and the Commercial Payer Council. Subscribe to stay updated on our latest initiatives, events, and industry insights.